comprehensive -WSS

comprehensive

author：comprehensive 2025-09-29 15:04:42 - browse：87

Gilead office remdesivir — Yichuan Cao/Sipa USA

Gilead Sciences said Monday it will acquire CymaBay Therapeutics for $4.3 billion, adding a new treatment for a liver disease that is on track for approval later this year.

The deal values CymaBay at $32.50 per share, 27% higher than the stock’s close last Friday. That’s a relatively small takeout premium, but CymaBay shares have doubled in value since last fall on growing investor confidence in the company’s lead drug and speculation that the company could be acquired.

CymaBay’s drug, called seladelpar, is being developed for the treatment of primary biliary cholangitis, or PBC, a type of liver disease mainly affecting women that causes decreased liver function, and debilitating itching and fatigue. Progression of PBC to more advanced stages increases the risk of liver-related death.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Melinda French Gates resigns from Gates Foundation

WSS

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Pancreatic cancer is often deadly, but new discoveries are raising hope

MultiPlan and major insurers sued for alleged medical price

UnitedHealth financials solid despite Change Healthcare cyberattack

Medicare Advantage 2025 payments will dip, Biden administration says

UnitedHealth, in a surprise, takes aim at Steward’s physician group

entertainment

comprehensive

focus

23andMe had bad news about my health. I wish a person had delivered it

Getting Alzheimer's drug Leqembi to patients can be a challenge

Apple is now the first public company to be valued at $3 trillion

People with mental disorders often marry others with same

Trump demands the U.S. pay no more for drugs than other countries … again

Alzheimer's risk factor APOE4 may be a distinct form of the disease

At least 13 dead in Texas as scorching temps continue

Drug companies' payments and gifts affect physicians' prescribing

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Study: Black kids more likely to die after surgery than white kids

focus

After traumatic brain injury, life support decisions can use more time

After traumatic brain injury, life support decisions can use more time

Mass General Brigham physicians react to latest merger step

UnitedHealth financials solid despite Change Healthcare cyberattack

Study: Black kids more likely to die after surgery than white kids

Bird flu in milk supply is likely coming from asymptomatic cows

focus

focus

hotspot

entertainment